When should spironolactone (Aldactone) be started in a patient with reduced‑ejection‑fraction heart failure who is already on an angiotensin‑converting‑enzyme inhibitor (or angiotensin‑receptor blocker/angiotensin‑receptor‑neprilysin inhibitor) and a beta‑blocker at tolerated doses, is NYHA functional class II–IV, and has serum potassium ≤5 mmol/L and estimated glomerular filtration rate ≥30 mL/min?

When to Give Spironolactone in Heart Failure

Spironolactone should be started in patients with heart failure and reduced ejection fraction (LVEF ≤35%) who remain symptomatic (NYHA class II–IV) despite optimized therapy with an ACE inhibitor (or ARB/ARNI) and a beta-blocker, provided serum potassium is ≤5.0 mmol/L and eGFR is >30 mL/min/1.73 m². 1, 2

Patient Selection Criteria

Mandatory Prerequisites

• LVEF ≤35% documented by echocardiography 1
• NYHA functional class II–IV symptoms persisting despite guideline-directed medical therapy 1
• Already receiving an ACE inhibitor (or ARB if ACE-intolerant, or ARNI) at tolerated doses 1, 2
• Already receiving a beta-blocker (bisoprolol, carvedilol, or metoprolol succinate) at tolerated doses 1, 2
• Serum potassium ≤5.0 mmol/L at baseline 1, 3
• eGFR >30 mL/min/1.73 m² (or serum creatinine ≤2.5 mg/dL) 1, 3

Strongest Indication

• NYHA class III–IV heart failure derives the greatest mortality benefit from spironolactone 1, 2
• The landmark RALES trial demonstrated a 30% reduction in all-cause mortality specifically in patients with severe heart failure (NYHA class III–IV, LVEF ≤35%) 1, 2

Dosing Protocol

Initiation

• Start spironolactone 25 mg once daily in patients meeting the above criteria 1, 3
• For patients with eGFR 30–50 mL/min/1.73 m², consider initiating at 25 mg every other day due to heightened hyperkalemia risk 3

Titration

• Patients tolerating 25 mg daily may have their dose increased to 50 mg once daily as clinically indicated 1, 3
• If hyperkalemia develops on 25 mg daily, reduce to 25 mg every other day 3

Timing in the Treatment Algorithm

Sequential Approach (Recommended)

1. First: Initiate ACE inhibitor and titrate to target dose 1, 2
2. Second: Add beta-blocker once patient is euvolemic and stable, then titrate to target dose 1, 2
3. Third: Add spironolactone if symptoms persist at NYHA class II–IV despite optimized ACE inhibitor and beta-blocker therapy 1, 2, 4

Loop diuretics should be used throughout as needed to maintain euvolemia 1, 2

Absolute Contraindications

• Serum potassium >5.0 mmol/L at baseline 1, 3
• **eGFR <30 mL/min/1.73 m²** or serum creatinine >2.5 mg/dL 1, 3
• Concurrent use of potassium supplements or other potassium-sparing diuretics 1, 2
• Anuria 3

Monitoring Requirements

Initial Monitoring

• Check serum potassium and creatinine 5–7 days after starting spironolactone 1, 2
• Recheck every 5–7 days until values are stable 1

Ongoing Monitoring

• If potassium rises to ≥5.5 mmol/L: reduce dose by 50% or discontinue if it continues to rise 2
• Monitor renal function and electrolytes regularly during chronic therapy 1

Common Pitfalls and How to Avoid Them

Hyperkalemia Risk

• Avoid NSAIDs during spironolactone therapy, as they worsen renal function and increase hyperkalemia risk 1, 2
• Discontinue potassium supplements and other potassium-sparing diuretics before initiating spironolactone 1, 2
• Higher-dose ACE inhibitors (other than captopril) and baseline renal impairment predict hyperkalemia 5
• Real-world studies show hyperkalemia rates of 13–20% at 25–50 mg daily doses, higher than reported in clinical trials 6, 5

Renal Function Deterioration

• Discontinue spironolactone if serum creatinine increases by 30–50% from baseline 6
• Close monitoring is mandatory in patients with CKD stage 3–4 7

Gynecomastia

• Occurs in approximately 9% of male patients at mean doses of 26 mg daily 2
• Painful gynecomastia may necessitate discontinuation; consider switching to eplerenone 2

Evidence Base

The RALES trial (Level A evidence) enrolled 1,663 patients with LVEF ≤35% and NYHA class III–IV heart failure already receiving ACE inhibitors and diuretics 1, 2. Spironolactone 25–50 mg daily reduced:

• All-cause mortality by 30% (p <0.001) 1, 2
• Heart failure hospitalization by 35% (p <0.001) 1
• Both progressive heart failure death and sudden cardiac death 1

The EMPHASIS-HF trial extended these benefits to NYHA class II patients with LVEF ≤30–35%, showing a 37% reduction in cardiovascular death or heart failure hospitalization with eplerenone 1

Special Considerations

• Only 11% of RALES participants were on beta-blockers, yet mortality benefit was still significant 1, 2
• At low doses (12.5–50 mg daily), spironolactone's primary action is aldosterone antagonism rather than diuresis 2
• Spironolactone addresses aldosterone escape that occurs despite ACE inhibitor therapy, blocking myocardial fibrosis, endothelial dysfunction, and sympathetic activation 2